109132 ⎘
Structure or type of the nucleic acid; Type of nucleic acid Antisense
Liposomal system for drug delivery
#2102METHODS AND COMPOSITIONS FOR RNA-DIRECTED TARGET DNA MODIFICATION AND FOR RNA-DIRECTED MODULATION OF TRANSCRIPTION
#2103ANTISENSE-BASED THERAPEUTICS FOR TARGETING HTRA1 AND METHODS OF USE
#2104Methods and compositions for modulating gene expression using oligonucleotide based drugs administered in vivo or in vitro
#2105Compositions and methods for modulating Ataxin 3 expression
#2106Method for determining decrease in functions of hippocampus by using correlation between micro RNA and NMDA receptor, method for inhibiting decrease in functions, and method for screening for inhibitors of decrease in functions
#2107Compositions and their uses directed to huntingtin
#2108C/EBP ALPHA SHORT ACTIVATING RNA COMPOSITIONS AND METHODS OF USE
#2109CANCER TREATMENT
#2110STEREODEFINED SUB-MOTIF OPTIMISATION METHODS
#2111Cell-penetrating peptides for antisense delivery
#2112METHODS AND COMPOSITIONS FOR RNA-DIRECTED TARGET DNA MODIFICATION AND FOR RNA-DIRECTED MODULATION OF TRANSCRIPTION
#2113METHODS AND COMPOSITIONS FOR RNA-DIRECTED TARGET DNA MODIFICATION AND FOR RNA-DIRECTED MODULATION OF TRANSCRIPTION
#2114METHODS AND COMPOSITIONS FOR RNA-DIRECTED TARGET DNA MODIFICATION AND FOR RNA-DIRECTED MODULATION OF TRANSCRIPTION
#2115Dynamin 2 inhibitor for the treatment of centronuclear myopathies
#2116Combinations for the modulation of SMN expression
#2117Liposomal spherical nucleic acid (SNA) constructs presenting antisense oligonucleotides (ASO) for specific knockdown of interleukin 17 receptor mRNA
#2118RNA duplexes with single stranded phosphorothioate nucleotide regions for additional functionality
#2119ApoCIII and the Treatment and Diagnosis of Diabetes
#2120Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
#2121Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
#2122RNAi agents and compositions for inhibiting expression of apolipoprotein C-III (APOC3)
#2123Therapy specific, pre-programmed auto injection device
#2124Compositions and methods for inhibiting HMGB1 expression
#2125Treatment of increased lipid levels with sterol regulatory element binding protein cleavage-activating protein (SCAP) inhibitors
#2126Treatment of increased lipid levels with sterol regulatory element binding transcription factor 1 (SREBF1) inhibitors
#2127TREATMENT OF GLIAL CELL DERIVED NEUROTROPHIC FACTOR (GDNF) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO GDNF
#2128ANTISENSE POLYNUCLEOTIDES TO INDUCE EXON SKIPPING AND METHOD OF TREATING DYSTROPHIES
#2129Methods for the treatment of Leber congenital amaurosis
#2130MicroRNA Compounds and Methods for Modulating MIR-21 Activity
#2131Oligonucleotide comprising an inosine for treating DMD
#2132Gapmers and methods of using the same for the treatment of muscular dystrophy
#2133METHODS OF TREATING CANCER USING TIGIT INHIBITORS AND ANTI-CANCER AGENTS
#2134Exosomal loading using hydrophobically modified oligonucleotides
#2135RNAi agents and compositions for inhibiting expression of Asialoglycoprotein receptor 1
#2136Splice Switching Oligomers for TNF Superfamily Receptors and Their Use in Treatment of Disease
#2137Methods and compositions for inhibiting expression of LDHA
#2138Antisense oligonucleotides for inducing exon skipping and methods of use thereof
#2139ANTISENSE ANTIBACTERIAL COMPOUNDS AND METHODS
#2140Oligonucleotide inhibiting the expression of Chop
#2141Reducing nonsense-mediated MRNA decay
#2142Method for producing complex of RNA molecule and peptide, and utilization thereof
#2143NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND METHODS OF INDUCING EXON SKIPPING
#2144METHODS AND COMPOSITIONS FOR RNA-DIRECTED TARGET DNA MODIFICATION AND FOR RNA-DIRECTED MODULATION OF TRANSCRIPTION
#2145Modulators of MALAT1 expression
#2146Peptide oligonucleotide conjugates
#2147COMPOSITIONS AND METHODS FOR REGULATION OF IMMUNE CELL ACTIVATION AND PROLIFERATION
#2148METHODS AND COMPOSITIONS FOR MODULATING APOLIPOPROTEIN (A) EXPRESSION
#2149ANTISENSE COMPOUNDS
#2150MODULATORY POLYNUCLEOTIDES
#2151RNAi-BASED THERAPEUTICS FOR TARGETING HTRA1 AND METHODS OF USE
#2152GALNAC DERIVATIVES
#2153Single-Stranded RNAI Oligonucleotides Targeting APOC-III
#2154Modulation of huntingtin expression
#2155Beta catenin nucleic acid inhibitor molecule
#2156Dynamic pharmacokinetic-modifying anchors
#2157MODIFYING THE SPECIFICITY OF NON-CODING RNA MOLECULES FOR SILENCING GENE EXPRESSION IN EUKARYOTIC CELLS
#2158Pharmaceutical use of FAM19A5 involved in regulating gliogenesis
#2159RNA-modulating agents
#2160Oligomers
#2161CHANNEL MODULATORS
#2162RNA molecules
#2163Treatment of hepatotoxicity with IL-11 antibody
#2164COMPOSITIONS AND METHODS FOR REGULATION OF GENE EXPRESSION WITH, AND DETECTION OF, FOLINIC ACID AND FOLATES
#2165Antisense oligonucleotides for the treatment of leber congenital amaurosis
#2166Stabilized HNF4A saRNA compositions and methods of use
#2167HNF4A saRNA compositions and methods of use
#2168Modifying the specificity of plant non-coding RNA molecules for silencing gene expression
#2169Antisense oligomers targeting PCSK9
#2170Methods and compositions using RNA interference and antisense oligonucleotides for inhibition of KRAS
#2171SMALL GUIDE ANTISENSE NUCLEIC ACID AND USE THEREOF
#2172Human antibodies to the human glucagon receptor and methods of use thereof to lower blood glucose or ketone levels
#2173Oligonucleotides for reduction of PD-L1 expression
#2174TENEURIN C-TERMINAL ASSOCIATED PEPTIDES (TCAP) AND METHODS AND USES THEREOF
#2175Antisense oligonucleotide and composition for prevention or treatment of glycogen storage disease type Ia
#2176METHODS FOR DIAGNOSING HUNTINGTON'S DISEASE
#2177Channel modulators
#2178Compositions and methods for modulation of protein aggregation
#2179Lipid formulated compositions and methods for inhibiting expression of serum amyloid A gene
#2180Methods and means for efficient skipping of exon 45 in Duchenne muscular dystrophy pre-mRNA
#2181Antisense oligonucleotides for treatment of cancer stem cells
#2182METHODS OF TREATING DIABETES AND/OR PROMOTING SURVIVAL OF PANCREATIC ISLETS AFTER TRANSPLANTATION
#2183Compositions for modulating expression of C9ORF72 antisense transcript
#2184COMPOSITIONS FOR MODULATING C9ORF72 EXPRESSION
#2185Morpholino modified oligomeric compounds
#2186BICYCLIC PEPTIDE OLIGONUCLEOTIDE CONJUGATES
#2187Reducing intron retention
#2188Agents useful in treating facioscapulohumeral muscular dystrophy
#2189Compositions and methods comprising histidyl-tRNA synthetase splice variants having non-canonical biological activities
#2190Nucleic acid oligomers and uses therefor
#2191ANTISENSE OLIGONUCLEOTIDE DIRECTED REMOVAL OF PROTEOLYTIC CLEAVAGE SITES, THE HCHWA-D MUTATION, AND TRINUCLEOTIDE REPEAT EXPANSIONS
#2192Immunosuppression-reverting oligonucleotides inhibiting the expression of CD39
#2193COMPOSITIONS AND METHODS FOR MODULATING HBV EXPRESSION
#2194Functional nucleic acid molecule and use thereof
#2195Biodegradable lipids for delivery of nucleic acids
#2196Splice inhibiting oligonucleotides
#2197Inhibition of LET7I as a means to enhance the protective effect of progesterone against stroke
#2198Antisense Compounds and Uses Thereof
#2199ANTISENSE OLIGONUCLEOTIDES FOR MODULATING RELA EXPRESSION
#2200Compositions and methods comprising histidyl-tRNA synthetase splice variants having non-canonical biological activities
#2201Targeting synaptogyrin-3 in tauopathy treatment
#2202Oligonucleotide analogues incorporating 5-aza-cytosine therein
#2203Methods and compositions for improving exercise endurance, performance, or tolerance
#2204Long noncoding RNAs in pulmonary airway inflammation
#2205Compositions and methods for messenger RNA inhibitors
#2206METHODS FOR TREATING OR PREVENTING CONTACT-ACTIVATION PATHWAY-ASSOCIATED DISEASES USING iRNA COMPOSITIONS TARGETING FACTOR XII (HAGEMAN FACTOR) (F12)
#2207LACTATE DEHYDROGENASE A (LDHA) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
#2208Inducible expression of genes in algae
#2209Allele-specific therapy for Huntington disease haplotypes
#2210Antisense oligonucleotides for inducing exon skipping and methods of use thereof
#2211Compounds and methods for reducing Tau expression
#2212Polycomb-Associated Non-Coding RNAs
#2213Targeted RNA editing
#2214Compositions and methods for non-antibiotic treating of bacterial infections by blocking or disrupting bacterial genes involved in virulence or viability
#2215Modulators of PCSK9 expression
#2216Antagonists of Products of the HS.459642 Unigene Cluster for the Inhibition of Proliferation, Development or Differentiation of Stem Cells Including Cancer Stem Cells
#2217Methods and compositions for treating cancers and enhancing therapeutic immunity by selectively reducing immunomodulatory M2 monocytes
#2218Methods And Compositions For Controlling Cardiac Fibrosis And Remodeling
#2219Compositions and methods to control insect pests
#2220Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
#2221PKLR inhibition in the treatment of NAFLD and HCC
#2222COMPOUNDS AND METHODS FOR MODULATING TMPRSS6 EXPRESSION
#2223METHOD OF TREATING KELOIDS OR HYPERTROPHIC SCARS USING ANTISENSE COMPOUNDS TARGETING CONNECTIVE TISSUE GROWTH FACTOR (CTGF)
#2224MODULATION OF HEPATITIS B VIRUS (HBV) EXPRESSION
#2225Brush polymer-assisted compaction of oligonucleotides
#2226EXON SKIPPING OLIGOMER CONJUGATES FOR MUSCULAR DYSTROPY
#2227Nucleic acid suppressing expression of APCS
#2228Compositions of self-reporting transposon (SRT) constructs and methods for mapping transposon insertions
#2229Antisense oligonucleotides (ODN) against SMAD7 and uses thereof in medical field
#2230Antisense oligonucleotides for the treatment of eye disease
#2231COMPOSITIONS AND METHODS FOR MODULATION OF SMN2 SPLICING
#2232Modulators of FOXP3 expression
#2233Systems and methods for the control of acute hepatopancreatic necrosis disease
#2234USP30 INHIBITORS AND METHODS OF USE
#2235METHODS OF MODULATING PROTEIN EXPRESSION FROM THE MENA-RIBONUCLEOPROTEIN COMPLEX IN CELLS
#2236Lipids for use in lipid nanoparticle formulations
#2237Virus like particle
#2238Therapeutic splice-switching oligonucleotides
#2239INHIBITION OF VASCULAR ENDOTHELIAL CELL-MEDIATED PHAGOCYTIC PROCESSES FOR TREATMENT OF DEMYELINATING CONDITIONS
#2240LncRNAs for therapy and diagnosis of cardiac hypertrophy
#2241PUM 1 protein as target for virus inhibition
#2242COMPOSITIONS AND METHODS FOR ENHANCED INTESTINAL ABSORPTION OF CONJUGATED OLIGOMERIC COMPOUNDS
#2243ANTISENSE OLIGONUCLEOTIDES FOR MODULATING HTRA1 EXPRESSION
#2244SMN2 element 1 antisense compositions and methods and uses thereof
#2245Modulating RNA Interactions with Polycomb Repressive Complex 1 (PRC1)
#2246Antisense therapies for treating cancer
#2247METHODS AND COMPOSITIONS FOR MODULATING ALPHA-1-ANTITRYPSIN EXPRESSION
#2248Compositions and methods for inhibiting TIGIT gene expression
#2249Transbiotic Regulation of Bacterial Gene Expression
#2250MODULATORS OF COMPLEMENT FACTOR B
#2251RNA modulating oligonucleotides with improved characteristics for the treatment of neuromuscular disorders
#2252Antisense nucleic acids
#2253COMPOSITIONS AND METHODS FOR ENHANCING THE THERAPEUTIC POTENTIAL OF STEM CELLS
#2254S-ANTIGEN TRANSPORT INHIBITING OLIGONUCLEOTIDE POLYMERS AND METHODS
#2255Nucleic acid molecule for reduction of PAPD5 and PAPD7 mRNA for treating hepatitis B infection
#2256Oligonucleotide analogues targeting human LMNA
#2257Methods and means for treating DNA repeat instability associated genetic disorders
#2258Enzymatic replacement therapy and antisense therapy for Pompe disease
#2259A TRANSGENIC PLANT HAVING RESISTANCE TO A PHYTO-PATHOGENIC FUNGUS
#2260Treatment of Sirtuin (SIRT) related diseases by inhibition of natural antisense transcript to a Sirtuin (SIRT)
#2261Antisense compounds targeting genes associated with cystic fibrosis
#2262COMPOSITIONS AND METHODS FOR TREATING CONDITIONS ASSOCIATED WITH GAIN-OF-FUNCTION MUTATIONS IN KCNT1
#2263Compositions and methods for modulating growth hormone receptor expression
#2264Enhanced organogenesis through manipulation of LIN28/LET-7/DIS3L2
#2265TREATMENT OF ANGIOGENESIS-ASSOCIATED DISEASES USING RNA COMPLEXES THAT TARGET ANGPT2 AND PDGFB
#2266ANTISENSE NUCLEIC ACID FOR TREATING AMYOTROPHY
#2267Methods for reducing post-operative cognitive dysfunction (POCD)
#2268Methods and pharmaceutical compositions for the treatment of diseases associated with reduced CFTR function
#2269Modulation of angiopoietin-like 3 expression
#2270Functionally-modified oligonucleotides and subunits thereof
#2271Antisense nucleic acids
#2272P-ethoxy nucleic acids for liposomal formulation
#2273LACTATE DEHYDROGENASE A (LDHA) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
#2274In vitro nephrotoxicity screening assay
#2275Treatment of atopic dermatitis and asthma using RNA complexes that target IL4Rα, TRPA1, or F2RL1
#2276In vivo delivery of oligonucleotides
#2277Methods of reducing expression of x-inactivation escapee genes and autosomal genes
#2278Splicing-dependent transcriptional gene silencing or activation
#2279Vectors and compositions for treating hemoglobinopathies
#2280Antisense nucleic acids
#2281Functional Nucleic Acid Protective Vector Based On DNA Hydrogel, Preparation Method and Application Thereof
#2282Beta-TUBULIN, Beta-TUBULIN GENE AND APPLICATION OF GENE SEGMENT THEREOF
#2283POLYNUCLEOTIDE AGENTS TARGETING SERPINC1 (AT3) AND METHODS OF USE THEREOF
#2284DELIVERY OF PACKAGED RNA TO MAMMALIAN CELLS
#2285Antisense nucleic acids
#2286Adoptive cell therapy using spherical nucleic acids (SNAs)
#2287Methods for identification, assessment, prevention, and treatment of cancer using PD-L1 isoforms
#2288Therapeutic uses and methods
#2289Methods for Producing Enteroendocrine Cells That Make and Secrete Insulin
#2290MODULATION OF APOLIPOPROTEIN C-III (APOCIII) EXPRESSION IN LIPODYSTROPHY POPULATIONS
#2291POLYNUCLEOTIDE AGENTS TARGETING COMPLEMENT COMPONENT C5 AND METHODS OF USE THEREOF
#2292Compositions for modulating Ataxin 2 expression
#2293NANOSCALE CARRIERS FOR THE DELIVERY OR CO-DELIVERY OF CHEMOTHERAPEUTICS, NUCLEIC ACIDS AND PHOTOSENSITIZERS
#2294Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
#2295Twist signaling inhibitor compositions and methods of using the same
#2296Serpina1 iRNA compositions and methods of use thereof
#2297Processes for preparing phosphorodiamidate morpholino oligomers
#2298Exon skipping oligomer conjugates for muscular dystrophy
#2299Compositions and methods for modulating MECP2 expression
#2300METHODS AND COMPOSITIONS FOR RNA-DIRECTED TARGET DNA MODIFICATION AND FOR RNA-DIRECTED MODULATION OF TRANSCRIPTION
#2301Viral vectors for treating neurogenic detrusor overactivity
#2302Allele specific modulators of P23H rhodopsin
#2303Anti-connexin compounds targeted to connexins and methods of use thereof
#2304Oligonucleotide therapy for Leber Congenital Amaurosis
#2305System and method for cell type-specific translation of RNA molecules in eukaryotes
#2306Amine-containing transfection reagents and methods for making and using same
#2307Oligonucleotides for inducing paternal UBE3A expression
#2308SELECTIVE ANTISENSE COMPOUNDS AND USES THEREOF
#2309MODULATION OF APOLIPOPROTEIN CIII (APOCIII) EXPRESSION
#2310Oligonucleotide compositions and methods thereof
#2311Nucleic acid compound and oligonucleotide
#2312COMPOSITIONS AND METHODS FOR MODULATING COMPLEMENT FACTOR B EXPRESSION
#2313Antisense Oligonucleotides for Treatment of Spinal Muscular Atrophy
#2314Inhibition of serotonin expression in gut enteroendocrine cells results in conversion to insulin-positive cells
#2315Oligonucleotides for reduction of PD-L1 expression
#2316Compositions for modulating SOD-1 expression
#2317Modulators of diacyglycerol acyltransferase 2 (DGAT2)
#2318ANTISENSE POLYNUCLEOTIDES TO INDUCE EXON SKIPPING AND METHOD OF TREATING DYSTROPHIES
#2319EXON SKIPPING COMPOSITIONS FOR TREATING MUSCULAR DYSTROPHY
#2320Compositions and methods for modulating SMN gene family expression
#2321Morpholino oligonucleotide manufacturing method
#2322Synergistic combination of oligonucleotides and chemotherapeutic for treating cancer
#2323Combination therapy with liposomal antisense oligonucleotides
#2324System for the biocontrol of pathogens in aquaculture and other animal systems
#2325METHODS FOR DOSING AND MONITORING SMAD7 ANTISENSE OLIGONUCLEOTIDE TREATMENT USING BIOMARKER LEVELS
#2326Treatment of down syndrome gene related diseases by inhibition of natural antisense transcript to a down syndrome gene
#2327Compositions and methods for modulation of IKBKAP splicing
#2328Methods for treating Alzheimer's disease
#2329Antisense antibacterial compounds and methods
#2330OLIGONUCLEOTIDES CONTAINING 2'-DEOXY-2'FLUORO-BETA-D-ARABINOSE NUCLEIC ACID (2'-FANA) FOR TREATMENT AND DIAGNOSIS OF RETROVIRAL DISEASES
#2331Inhibition of stress granule formation through manipulation of UBAP2L
#2332Methods of treating or alleviating joint diseases by administering an inhibitor of discoidin domain receptor 1 (DDR1)
#2333Antisense oligomers for treatment of conditions and diseases
#2334Oligomers and oligomer conjugates
#2335Antisense oligomers for treatment of conditions and diseases
#2336Antisense oligonucleotides to treat dystrophic epidermolysis bullosa
#2337Oligonucleotides for modulating ATXN2 expression
#2338Liposomal particles, methods of making same and uses thereof
#2339Oligomers
#2340Targeting human satellite II (HSATII)
#2341MODULATION OF APOLIPOPROTEIN C-III (APOCIII) EXPRESSION IN LIPOPROTEIN LIPASE DEFICIENT (LPLD) POPULATIONS
#2342Compositions for enhancing transport of molecules into cells
#2343STAT5a AND ITS FUNCTIONAL TUMOR SUPPRESSOR ANALOGS FOR TREATMENT OF MALIGNANCIES EXPRESSING NPM/ALK AND OTHER ONCOGENIC KINASES
#2344Targeted control of pests and pathogens by plant delivery of 2'F-ANA-oligonucleotides
#2345Oligonucleotides for modulating Tau expression
#2346Antisense oligonucleotides for inhibition of PD-L1 expression and treating cancer
#2347Methods of treating autism spectrum disorders
#2348Methods and compositions for the specific inhibition of glycolate oxidase (HAO1) by double-stranded RNA
#2349Costimulatory B7-H1 in renal cell carcinoma patients: indicator of tumor aggressiveness and potential therapeutic target
#2350EFFICIENT PROTEIN EXPRESSION IN VIVO USING MODIFIED RNA (MOD-RNA)
#2351Modulation of Factor 11 expression
#2352MARKERS SELECTIVELY DEREGULATED IN TUMOR-INFILTRATING REGULATORY T CELLS
#2353Methods and compositions for the specific inhibition of alpha-1 antitrypsin by double-stranded RNA
#2354High cAMP yielding yeast strain and use thereof
#2355Multiple oligonucleotide moieties on peptide carrier
#2356Methods for treating NLRP3 inflammasome-associated diseases, and methods of identifying agents useful therefor
#2357Methods for sub-typing and treating cancer
#2358Antisense oligonucleotides for use in treating Alzheimer's disease
#2359ANTISENSE COMPOUNDS TARGETING GENES ASSOCIATED WITH FIBRONECTIN
#2360METHODS AND COMPOSITIONS FOR TREATMENT OF IONIZING RADIATION RESISTANT TUMORS
#2361Genetic and pharmacological transcriptional upregulation of the repressed FXN gene as a therapeutic strategy for Friedreich ataxia
#2362METHODS AND COMPOSITIONS FOR TREATING SOLID TUMORS AND ENHANCING TUMOR VACCINES
#2363Antisense Compositions and Methods of Making and Using Same
#2364Formulation
#2365Antisense oligonucleotides that inhibit influenza virus replication and uses thereof
#2366ANTISENSE OLIGONUCLEOTIDES FOR MODULATING NFKB1 EXPRESSION
#2367Antisense oligonucleotides for the treatment of Stargardt disease
#2368Diagnosing COL6-related disorders and methods for treating same
#2369Compositions for modulating C9ORF72 expression
#2370Conjugated antisense compounds and their use
#2371OLIGONUCLEOTIDES FOR MODULATING ATXN2 EXPRESSION
#2372Methods and compositions for treating cancers using antisense
#2373BIOLOGICAL CONTROLS OF COLEOPTERAN PESTS
#2374SPLICE SWITCHING OLIGOMERS FOR TNF SUPERFAMILY RECEPTORS AND THEIR USE IN TREATMENT OF DISEASE
#2375Modulators of APOL1 expression
#2376Oligomeric compounds comprising α-β-constrained nucleic acid
#2377Exonic splicing enhancers and exonic splicing silencers
#2378Oligonucleotide complexes for use in RNA editing
#2379Sterile formulation comprising a stable phosphorothioate oligonucleotide
#2380Modified iRNA agents
#2381ANTISENSE OLIGONUCLEOTIDES FOR MODULATING RELB EXPRESSION
#2382ANTISENSE OLIGONUCLEOTIDES FOR MODULATING NFKB2 EXPRESSION
#2383Anti-ARID3a treatments for inflammatory disorders
#2384Bicyclic nucleosides and oligomers prepared therefrom
#2385Therapeutic targets for facioscapulohumeral muscular dystrophy
#2386Modulation of Lnc05 expression
#2387SCN9A antisense pain killer
#2388SNAP25 antisense oligonucleotides
#2389MODULATION OF TMPRSS6 EXPRESSION
#2390ANTISENSE OLIGONUCLEOTIDES FOR MODULATING REL EXPRESSION
#2391METHODS AND COMPOSITIONS FOR TREATING A SUBJECT WITH A SMAD7 ANTISENSE OLIGONUCLEOTIDE
#2392SELECTIVE ANTISENSE COMPOUNDS AND USES THEREOF
#2393Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
#2394ANTIVIRAL AGENT AND METHOD FOR TREATING VIRAL INFECTION
#2395Methods for intracellular delivery and enhanced gene targeting
#2396EXON SKIPPING COMPOSITIONS FOR TREATING MUSCULAR DYSTROPHY
#2397Single-stranded RNA-editing oligonucleotides
#2398COMPOSITIONS OF SMAD7 ANTISENSE OLIGONUCLEOTIDE AND METHODS OF TREATING OR PREVENTING PSORIASIS
#2399ANTISENSE OLIGONUCLEOTIDES DIRECTED AGAINST CONNECTIVE TISSUE GROWTH FACTOR AND USES THEREOF
#2400Antisense oligonucleotides for inducing exon skipping and methods of use thereof